<?xml version="1.0" encoding="UTF-8"?>
<p id="Par101">Following registration and re-induction therapy, an authorised member of staff at the trial research site will randomise participants into the study. Randomisation will be performed centrally using the Gen24 system. At the first randomisation (R1), following completion of ITD re-induction chemotherapy, eligible participants (see Table 
 <xref rid="Tab2" ref-type="table">2</xref> for details) will be randomised on a 1:1 basis to augmented ASCT (ASCT
 <sub>Aug</sub>) or conventional ASCT (ASCT
 <sub>Con</sub>).
</p>
